8-K: Neuraxis Inc. Completes Conversion of $4.9 Million in Promissory Notes to Preferred Stock

Neuraxis Inc. has converted approximately $4.9 million in promissory notes into 2,073,524 shares of Series B Preferred Stock following stockholder approval and the filing of necessary certificates.

Summary

• Neuraxis Inc. has converted $4,935,001.90 of principal owed under various convertible promissory notes into 2,073,524 shares of Series B Preferred Stock.
• The conversion occurred on September 9, 2024, following stockholder approval on August 15, 2024, and the filing of the Certificate of Designation with the State of Delaware.
• The promissory notes were issued to Flagstaff International, LLC and other accredited investors in multiple tranches between February and May 2024.
• The Series B Preferred Stock was created following an amendment to the company's Certificate of Incorporation and is convertible into common stock at any time without further consideration.
• The Series B Preferred Stock ranks senior to the common stock in terms of payments upon liquidation, dissolution, or winding up of the company.
• The conversion price for the notes was $2.38 per share.

Sentiment

Score: 7

Explanation: The document reflects a positive step in the company's financial structure by converting debt to equity, but also highlights the company's reliance on convertible debt. The conversion was expected and executed as planned.

Positives

• The conversion of promissory notes into preferred stock simplifies the company's capital structure.
• The company has successfully obtained stockholder approval for the creation of the Series B Preferred Stock.
• The company has secured significant funding through convertible notes from various investors.
• The Series B Preferred Stock provides a higher level of security for investors compared to common stock.

Negatives

• The conversion of debt to equity may dilute existing common shareholders.
• The company has relied heavily on convertible debt financing.

Risks

• The company's reliance on convertible debt financing may indicate challenges in securing traditional equity funding.
• The senior ranking of the Series B Preferred Stock could negatively impact common shareholders in the event of liquidation.
• The company's future performance will be critical to ensure the value of the converted preferred stock.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• The company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Industry Context

The conversion of debt to equity is a common practice for companies seeking to strengthen their balance sheet and simplify their capital structure, particularly in the biotech and emerging growth sectors. This move is often seen as a step towards future growth and potential public offerings.

Comparison to Industry Standards

• Many early-stage biotech companies rely on convertible debt financing to fund operations and research before securing larger equity investments.
• The conversion of debt to preferred stock is a standard mechanism to provide investors with a higher level of security and potential upside.
• The conversion price of $2.38 per share is typical for early-stage companies with potential for growth.
• Companies like XOMA Corporation and Agenus Inc. have used similar financing strategies in their early stages.

Stakeholder Impact

• Existing common shareholders may experience dilution due to the issuance of new preferred stock.
• Preferred stock holders now have a senior claim on assets in the event of liquidation.
• The conversion of debt to equity may improve the company's financial stability and attractiveness to future investors.

Key Dates

Keywords

Series B Preferred Stock, Convertible Notes, Stockholder Approval, Securities Purchase Agreement, Capital Structure, Debt Conversion, Flagstaff International, Accredited Investors